Back to today’s briefing

Story perspectives

FDA approves Moderna's first mRNA flu vaccine despite funding cuts

8/6/2026

35 7 Full Breakdown

Summary

Story summary

The U.S. Food and Drug Administration approved Moderna’s mRNA flu vaccine mFlusiva for adults 50-65 and 65+.
It is the first U.S. mRNA-based influenza vaccine, with trials showing up to 27 percent higher efficacy than standard shots and production possible in two to three months.
HHS Secretary Robert F. Kennedy, Jr., a vocal mRNA-vaccine critic, canceled millions of dollars in funding for mRNA vaccine research.

1 of 1

Story summary

The U.S. Food and Drug Administration approved Moderna’s mRNA flu vaccine mFlusiva for adults 50-65 and 65+.
It is the first U.S. mRNA-based influenza vaccine, with trials showing up to 27 percent higher efficacy than standard shots and production possible in two to three months.
HHS Secretary Robert F. Kennedy, Jr., a vocal mRNA-vaccine critic, canceled millions of dollars in funding for mRNA vaccine research.